氨基甲酸-(2-羟基-3-苯氧基丙酯) | 105959-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 氨基甲酸-(2-羟基-3-苯氧基丙酯)
• 英文名称: carbamic acid-(2-hydroxy-3-phenoxy-propyl ester)
• 英文别名: Carbamidsaeure-(β-oxy-γ-phenoxy-propylester)；Carbamidsaeure-(2-hydroxy-3-phenoxy-propylester)；(2-Hydroxy-3-phenoxypropyl) carbamate；(2-hydroxy-3-phenoxypropyl) carbamate
• CAS: 105959-07-7
• 化学式: C₁₀H₁₃NO₄
• 分子量: 211.218
• InChiKey: DIFNMSKZEMXPTK-UHFFFAOYSA-N

物化性质

• 沸点：
  453.1±35.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 ammonium hydroxide 作用下， 生成 氨基甲酸-(2-羟基-3-苯氧基丙酯)
  参考文献：
  名称：

  DE284975

  摘要：

  公开号：

文献信息

• Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome
  申请人：Numazawa Toshihiko

  公开号：US11364218B2

  公开（公告）日：2022-06-21

  A method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome is provided. The method comprises administering to a subject in need thereof a pharmaceutical composition containing one or more kinds of compounds of the following structure: wherein R is an alkyloxy group containing 1 to 3 carbon atoms or a halogen group.

  本发明提供了一种治疗或预防情绪障碍、精神障碍和/或慢性疲劳综合征的方法。该方法包括向有需要的受试者施用药物组合物，其中含有一种或多种以下结构的化合物： 其中 R 是含有 1 至 3 个碳原子的烷氧基或卤素基团。
• Pharmaceutical composition
  申请人：NUMAZAWA Toshihiko

  公开号：US20200138769A1

  公开（公告）日：2020-05-07

  Provided is a pharmaceutical composition which rarely causes adverse side effects, e.g., increase or decrease in body weights, decrease in appetite and decrease in libido, and withdrawal symptoms, and is effective for the treatment of mood disorder, mental disorder and/or chronic fatigue syndrome. The pharmaceutical composition comprises at least one compound having the following structure: where R represents an alkyloxy group having 1 to 3 carbon atoms or a halogen group.
• METHOD OF TREATING OR PREVENTING MOOD DISORDERS, MENTAL DISORDERS, AND/OR CHRONIC FATIGUE SYNDROME
  申请人：NUMAZAWA Toshihiko

  公开号：US20210015781A1

  公开（公告）日：2021-01-21

  A method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome is provided. The method comprises administering to a subject in need thereof a pharmaceutical composition containing one or more kinds of compounds of the following structure: wherein R is an alkyloxy group containing 1 to 3 carbon atoms or a halogen group.
• Drug For Treating And Preventing Dementia
  申请人：NUMAN LABO LLC

  公开号：US20220362202A1

  公开（公告）日：2022-11-17

  The pharmaceutical composition for treating dementia, comprising a mephenesin analogue compound and/or a compound with a carbamate structure. A therapeutic drug that can fundamentally treat dementia without causing side effects, such as an increase/decrease in body weight, loss of appetite, sexual debility, and symptoms of withdrawal can be provided with the pharmaceutical composition defined in the present invention. Combining this pharmaceutical composition with other pharmaceutical compositions, including cholinesterase inhibitors, can provide the most certain treatment method according to the symptoms.
• DE284975
  申请人：——

  公开号：——

  公开（公告）日：——